Foresite Capital Management IV, LLC

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Foresite Capital Management IV, LLC reported 5 stock positions worth $153.0 million. Its top holding was Pharvaris (PHVS) at 53.2% of the portfolio, followed by Kura Oncology (KURA, 23.6%) and Syndax Pharmaceuticals (SNDX, 11.0%). Compared with Q2 2024, it opened 1 new position and added to 1. The biggest buy was a new position in Relay Therapeutics (RLAY).

Most Recent 13F
Q2 2026
Location
WEST HOLLYWOOD, CA
CIK
0001704132
Portfolio Value
$153.0M (Q3 2024)
SEC Filing
0001104659-24-118737 ↗ filed Nov 14, 2024

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $197.9M Q1 2024 Q2 2024: $148.8M Q2 2024 Q3 2024: $153.0M $153.0M Q3 2024 Q4 2024: $108.8M Q4 2024 Q1 2025: $111.1M Q1 2025 Q2 2025: $123.8M Q2 2025 Q3 2025: $182.6M Q3 2025 Q4 2025: $229.7M Q4 2025 Q1 2026: $237.1M Q1 2026 Q2 2026: $290.2M Q2 2026

Holdings 5 stocks · $153.0M
PHVS Pharvaris NV 53.23% 4,397,881 $81.4M Add +2.4%
KURA Kura Oncology Inc. 23.62% 1,849,947 $36.1M No change
SNDX Syndax Pharmaceuticals Inc. 11.01% 875,000 $16.8M No change
LYEL Lyell Immunopharma Inc. 7.51% 8,325,000 $11.5M No change
RLAY Relay Therapeutics Inc. 4.63% 1,000,000 $7.1M New

Portfolio Sells Q2 2024 → Q3 2024
None this quarter.

Portfolio Buys Q2 2024 → Q3 2024
RLAY Relay Therapeutics Inc. New 4.63% +4.63
PHVS Pharvaris NV Add +2.4% 53.23% −1.00

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 6$290.2MPHVS, CYTK, EIKN, RLAY, XENE
Q1 2026 8$237.1MPHVS, CYTK, EIKN, LYEL, RLAY
Q4 2025 7$229.7MPHVS, CYTK, LYEL, MAZE, RLAY
Q3 2025 6$182.6MPHVS, CYTK, MAZE, LYEL, XENE
Q2 2025 6$123.8MPHVS, MAZE, LYEL, XENE, KURA
Q1 2025 5$111.1MPHVS, MAZE, LYEL, KURA, RLAY
Q4 2024 4$108.8MPHVS, KURA, LYEL, RLAY
Q3 2024 5$153.0MPHVS, KURA, SNDX, LYEL, RLAY
Q2 2024 4$148.8MPHVS, KURA, SNDX, LYEL
Q1 2024 5$197.9MPHVS, KURA, KNTE, SNDX, LYEL